Understanding how certain enzymes help in making halogenated compounds.
Dissect Mechanism of Iron(II)/2-Oxoglutarate Dependent Enzymes Catalyzed Halogenation in Nucleotide Biosynthesis
This study is looking at how certain enzymes help add special chemicals to building blocks of DNA, which could lead to new ways to create treatments for cancer and improve existing therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Carnegie-Mellon University NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10918144 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which iron and 2-oxoglutarate-dependent enzymes catalyze the halogenation process in nucleotide biosynthesis. By focusing on the radical halogenation reactions, the study aims to uncover how these enzymes can selectively transfer halide radicals to substrates, which is crucial for developing new chemical synthesis methods. The research employs advanced biochemical techniques to analyze the enzyme mechanisms and identify factors that influence their activity. Patients may benefit from the findings as they could lead to the development of novel anti-cancer agents and improved therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would include individuals with cancer who may be treated with novel therapeutic agents derived from these findings.
Not a fit: Patients with conditions unrelated to cancer or those who do not respond to current anti-cancer therapies may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new and more effective anti-cancer drugs.
How similar studies have performed: Other research has shown success in utilizing similar enzyme mechanisms for drug development, indicating a promising avenue for this approach.
Where this research is happening
Pittsburgh, United States
- Carnegie-Mellon University — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Guo, Yisong — Carnegie-Mellon University
- Study coordinator: Guo, Yisong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.